JP2004527489A - フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 - Google Patents

フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 Download PDF

Info

Publication number
JP2004527489A
JP2004527489A JP2002567272A JP2002567272A JP2004527489A JP 2004527489 A JP2004527489 A JP 2004527489A JP 2002567272 A JP2002567272 A JP 2002567272A JP 2002567272 A JP2002567272 A JP 2002567272A JP 2004527489 A JP2004527489 A JP 2004527489A
Authority
JP
Japan
Prior art keywords
compound
polymer
pharmaceutical composition
solid dispersion
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002567272A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004527489A5 (cg-RX-API-DMAC7.html
Inventor
ベイトマン，ニコラ
カヒル，ジュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2004527489A publication Critical patent/JP2004527489A/ja
Publication of JP2004527489A5 publication Critical patent/JP2004527489A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2002567272A 2001-02-27 2002-02-25 フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物 Pending JP2004527489A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0104752.1A GB0104752D0 (en) 2001-02-27 2001-02-27 Pharmaceutical compositions
PCT/SE2002/000327 WO2002067904A1 (en) 2001-02-27 2002-02-25 Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer

Publications (2)

Publication Number Publication Date
JP2004527489A true JP2004527489A (ja) 2004-09-09
JP2004527489A5 JP2004527489A5 (cg-RX-API-DMAC7.html) 2005-12-22

Family

ID=9909545

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002567272A Pending JP2004527489A (ja) 2001-02-27 2002-02-25 フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物

Country Status (14)

Country Link
US (1) US20040138231A1 (cg-RX-API-DMAC7.html)
EP (1) EP1365746A1 (cg-RX-API-DMAC7.html)
JP (1) JP2004527489A (cg-RX-API-DMAC7.html)
KR (1) KR20040011469A (cg-RX-API-DMAC7.html)
CN (1) CN1533268A (cg-RX-API-DMAC7.html)
BR (1) BR0206960A (cg-RX-API-DMAC7.html)
CA (1) CA2435815A1 (cg-RX-API-DMAC7.html)
GB (1) GB0104752D0 (cg-RX-API-DMAC7.html)
IL (1) IL156830A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03006746A (cg-RX-API-DMAC7.html)
NO (1) NO20033782D0 (cg-RX-API-DMAC7.html)
NZ (1) NZ527080A (cg-RX-API-DMAC7.html)
WO (1) WO2002067904A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200305386B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
WO2004105728A2 (en) * 2003-05-27 2004-12-09 Ranbaxy Laboratories Limited Solid dispersions of cefpodoxime proxetil and processes for their preparation
KR100531612B1 (ko) * 2003-08-12 2005-11-28 경동제약 주식회사 지속성 탐스로신 정제의 제조방법 및 그에 따른 지속성탐스로신 정제
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
CA2720851A1 (en) * 2008-04-15 2009-10-22 Schering Corporation Oral pharmaceutical compositions in a molecular solid dispersion
LT2346495T (lt) * 2008-10-07 2016-10-10 Astrazeneca Uk Limited Farmacinė kompozicija 514
US20170087134A1 (en) * 2010-07-12 2017-03-30 Salix Pharmaceuticals, Ltd Formulations of rifaximin and uses thereof
CN104188893A (zh) * 2014-08-18 2014-12-10 赵明亮 一种盐酸环丙沙星口服固体制剂及其制备工艺
KR20240124428A (ko) 2016-09-30 2024-08-16 샐릭스 파마슈티컬스 인코포레이티드 리팍시민의 고체 분산물 형태
WO2025078941A1 (en) * 2023-10-09 2025-04-17 Intas Pharmaceuticals Ltd. Pharmaceutical composition of pirtobrutinib

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57120518A (en) * 1981-01-19 1982-07-27 Tanabe Seiyaku Co Ltd Preparation of microcapsule
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
TW212139B (cg-RX-API-DMAC7.html) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
WO1992018106A1 (fr) * 1991-04-16 1992-10-29 Nippon Shinyaku Co., Ltd. Procede de production d'une dispersion solide
US6312726B1 (en) * 1993-08-20 2001-11-06 Nippon Shinyaku Co., Ltd. Gastric remaining preparation, swollen molding, and production process
IL139406A (en) * 1998-05-02 2004-07-25 Astrazeneca Ab Heterocyclic derivatives inhibiting factor XA, pharmaceutical preparations containing them and their use as a drug in the treatment of diseases or conditions mediated by factor XA in warm-blooded animals
AU782469B2 (en) * 1999-12-23 2005-08-04 Mayne Pharma International Pty Ltd Improved pharmaceutical compositions for poorly soluble drugs

Also Published As

Publication number Publication date
NZ527080A (en) 2005-02-25
WO2002067904A1 (en) 2002-09-06
ZA200305386B (en) 2004-10-11
BR0206960A (pt) 2004-03-09
CA2435815A1 (en) 2002-09-06
NO20033782L (no) 2003-08-26
KR20040011469A (ko) 2004-02-05
US20040138231A1 (en) 2004-07-15
MXPA03006746A (es) 2003-10-24
IL156830A0 (en) 2004-02-08
NO20033782D0 (no) 2003-08-26
GB0104752D0 (en) 2001-04-18
CN1533268A (zh) 2004-09-29
EP1365746A1 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
JP5775071B2 (ja) アピキサバンの製剤形
KR102593075B1 (ko) 셀렉시파그를 포함하는 약학 조성물
JP7425794B2 (ja) 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用
CA2720851A1 (en) Oral pharmaceutical compositions in a molecular solid dispersion
WO2001095912A1 (fr) Compositions permettant de reguler la plage et/ou la vitesse de liberation du ph
CN105232488B (zh) 一种含有利伐沙班的固体药物组合物
US20210369620A1 (en) Solid dosage forms with high active agent loading
EP3435985A1 (en) Granulate formulation of 5-methy!-1-pheny!-2(1h)-pyridone and method of making the same
JPWO2008066102A1 (ja) 徐放性製剤
IL310203A (en) Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
WO2008027600A2 (en) Imatinib compositions
JP2004527489A (ja) フタル酸ヒドロキシプロピルメチルセルロースポリマーの固体分散物を含む医薬組成物
AU2023274142B2 (en) Crystal
KR20220087443A (ko) 셀렉시파그를 포함하는 약제학적 조성물
CN110193012B (zh) 一种氧代吡啶酰胺类衍生物的药物组合物及其制备方法
TW200817000A (en) New paediatric indications for direct thrombin inhibitors
ZA200409237B (en) Immediate release pharmaceutical formulation.
US6333361B1 (en) Pharmaceutical composition containing zafirlukast
CN114916221A (zh) 一种高生物利用度的索拉非尼药物组合物及应用
US20240293323A1 (en) Pharmaceutical compositions of an epidermal growth factor receptor inhibitor
KR101823071B1 (ko) 텔미사르탄-함유 정제의 제조방법
KR102222774B1 (ko) 에독사반을 포함하는 약학적 제제 및 이의 제조방법
AU2002233882A1 (en) Pharmaceutical composition which comprise a solid dispersion of a hydroxypropylmethylcellulose phthalate polymer
EP4552633A1 (en) Pharmaceutical compositions comprising amorphous solid solutions of rivaroxaban and copovidone and preparation methods thereof
KR20250136432A (ko) 밀벡시안 제약 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081009

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090109

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090401